Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is a biotechnology company focused on developing novel treatments for inflammatory and immune-mediated diseases. With its lead program, SL-325, showing promising results in a Phase 1 trial, and plans for a Phase 2b trial in Crohn's disease, the company is well-positioned for success. The Phase 1 data demonstrate a clean DR3 mechanism with low immunogenicity and potential for convenient quarterly dosing, setting it apart from its competitors. With a strong pipeline and potential for market differentiation, Shattuck Labs has the potential for significant revenue growth in the future, making it an attractive investment opportunity.

Bears say

Shattuck Labs is a biotechnology company with a promising lead asset, SL-325, targeting the TL1A/DR3 inflammation pathway for inflammatory bowel disease (IBD). However, with limited clinical data and a long development timeline, the company's success is dependent on the results of its upcoming clinical trials. Additionally, the company's pipeline optionality and potential for lower immunogenicity are still speculative, making this a high-risk investment.

Shattuck Labs (STTK) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 8 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.